#Germany #Munich #Geographic Atrophy #Complement Therapeutics #CTx001

Complement Therapeutics Initiates Opti-GAIN Study

In a significant advancement for treating vision loss due to age-related macular degeneration (AMD), Complement Therapeutics GmbH has recently announced that the first patient has been dosed in its Opti-GAIN clinical trial. This Phase I/II study is testing CTx001, an investigational gene therapy targeting Geographic Atrophy (GA) associated with AMD.

Background on AMD and Geographic Atrophy

Age-related macular degeneration is a leading cause of vision impairment in the elderly, with Geographic Atrophy being one of its more severe forms. Currently, there is a notable lack of effective treatments for GA. The Opti-GAIN trial aims to address this unmet need by evaluating a novel treatment approach specifically designed to slow down or halt the progression of this condition.

The Opti-GAIN Study

The Opti-GAIN study involves multiple sites and is focused on assessing the safety, tolerability, and early effectiveness of CTx001, which is delivered through a single subretinal injection. The first phase of the trial is an open-label, dose-escalation study that will analyze responses across three different dosing cohorts followed by a dose-expansion phase. This structure is designed to provide a robust dataset for determining the most effective dosing strategy moving forward.

Dr. Arshad M. Khanani, the trial's Chief Investigator and a prominent figure in clinical research at Sierra Eye Associates in Reno, Nevada, emphasized the importance of exploring innovative methods for patients suffering from progressive vision loss due to GA. He expressed his enthusiasm for the ongoing study, stating, "It’s an honor to administer CTx001 to the first participant in this significant trial. I look forward to collaborating with Complement Therapeutics to further explore this promising gene therapy method."

Mechanism of Action of CTx001

CTx001 is an AAV2-based investigational therapy designed to transduce retinal cells with a construct that encodes mini-CR1, an essential molecule that modulates both the classical and alternative pathways of the complement system. This gene therapy aims to produce mini-CR1 within the retina, potentially leading to broad ocular biodistribution and significant therapeutic effects.

Complementing Research Initiatives

Complement Therapeutics is advancing the Opti-GAIN study concurrently with its ongoing Pre-GAIN natural history study, which aims to gather insights about the progression of GA and inform patient selection for clinical trials. By combining natural history data with interventional study results, the company hopes to refine its clinical development strategies and ultimately provide better outcomes for patients.

Dr. Rafiq Hasan, the CEO of Complement Therapeutics, described the initiation of patient dosing in Opti-GAIN as a pivotal moment for the company and the field of retinal therapies. He believes that the combination of CTx001's innovative design and the integrated research strategy of the Opti-GAIN and Pre-GAIN studies will provide critical insights into effective treatment pathways for GA.

Conclusion

The initiation of the Opti-GAIN study signals a promising new phase in the treatment of Geographic Atrophy associated with AMD. As this phase I/II trial progresses, the potential benefits of CTx001 could pave the way for groundbreaking advancements in therapies for retinal diseases, ultimately enhancing the quality of life for countless patients affected by vision deterioration. Stay tuned to ClinicalTrials.gov for updates on this exciting study and more from Complement Therapeutics.